Neutrisci International Stock Today
| NU Stock | CAD 13.53 0.41 2.94% |
Performance0 of 100
| Odds Of DistressOver 67
|
NeutriSci International is selling for under 13.53 as of the 29th of November 2024; that is 2.94 percent decrease since the beginning of the trading day. The stock's lowest day price was 13.49. NeutriSci International has more than 67 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for NeutriSci International are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
NeutriSci International Inc. develops, markets, and distributes nutraceutical products in Canada. NeutriSci International Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. NEUTRISCI INTERNATIONAL is traded on Commodity Exchange in Exotistan. The company has 178.42 M outstanding shares of which 4.87 K shares are now shorted by private and institutional investors with about 0.44 trading days to cover. More on NeutriSci International
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NeutriSci Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. NeutriSci International's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding NeutriSci International or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | Glen Rehman | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
NeutriSci International's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to NeutriSci International's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsNeutriSci International can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NeutriSci International's financial leverage. It provides some insight into what part of NeutriSci International's total assets is financed by creditors.
| |||||
NeutriSci International (NU) is traded on TSX Venture Exchange in Canada and employs 8 people. NeutriSci International is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 892.12 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate NeutriSci International's market, we take the total number of its shares issued and multiply it by NeutriSci International's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. NeutriSci International conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 178.42 M outstanding shares of which 4.87 K shares are now shorted by private and institutional investors with about 0.44 trading days to cover.
NeutriSci International currently holds about 152.47 K in cash with (264.69 K) of positive cash flow from operations.
Check NeutriSci International Probability Of Bankruptcy
Ownership AllocationNeutriSci International maintains a total of 178.42 Million outstanding shares. Roughly 98.97 % of NeutriSci International outstanding shares are held by general public with 1.03 pct. owned by insiders and only 0.0 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check NeutriSci Ownership Details
NeutriSci International Risk Profiles
Although NeutriSci International's alpha and beta are two of the key measurements used to evaluate NeutriSci International's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.92 | |||
| Standard Deviation | 2.59 | |||
| Variance | 6.71 | |||
| Risk Adjusted Performance | (0.02) |
NeutriSci Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in NeutriSci International without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
NeutriSci International Corporate Management
Elected by the shareholders, the NeutriSci International's board of directors comprises two types of representatives: NeutriSci International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeutriSci. The board's role is to monitor NeutriSci International's management team and ensure that shareholders' interests are well served. NeutriSci International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeutriSci International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thierry Sorhaitz | Vice Marketing | Profile | |
| Jaycee Waters | Operations Manager | Profile | |
| Johnathan JD | Portfolio Mang | Profile | |
| CFA Spalding | Portfolio Mang | Profile | |
| William IV | VP Trustee | Profile | |
| John Chisholm | Chief Officer | Profile |
Additional Tools for NeutriSci Stock Analysis
When running NeutriSci International's price analysis, check to measure NeutriSci International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeutriSci International is operating at the current time. Most of NeutriSci International's value examination focuses on studying past and present price action to predict the probability of NeutriSci International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeutriSci International's price. Additionally, you may evaluate how the addition of NeutriSci International to your portfolios can decrease your overall portfolio volatility.